

LIST OF TABLES

Table No.	Table Caption	Pg. No.
Table 2-1	Physicochemical Properties of PTX	27
Table 2-2	Work done on PTX	29
Table 2-3	Physicochemical Properties of CBP	32
Table 2-4	Work done on CBP	33
Table 2-5	Work done on ultradeformable vesicles	41
Table 3-1	Mean Peak area values for calibration plot for PTX	57
Table 3-2	Intraday and Interday precision values for PTX	58
Table 3-3	Results for accuracy of the method	59
Table 3-4	Mean peak area values for HPLC calibration plot for CBP	62
Table 3-5	Intraday and interday precision values for CBP	64
Table 3-6	Accuracy of the HPLC method for CBP	64
Table 4-1	Results of PTX crystallization study	77
Table 4-2	levels of hydration step process parameters	79
Table 4-3	Effect of hydration volume aliquots on entrapment efficiency	80
Table 4-4	Effect of hydration time on entrapment efficiency	80
Table 4-5	Effect of hydration temperature on entrapment efficiency	81
Table 4-6	Effect of residual hydration volume on entrapment efficiency	84
Table 5-1	Measures of qualitative risk assessment	89
Table 5-2	QTPP for PTX loaded UDNVs	92
Table 5-3	Qualitative Risk Assessment	94
Table 5-4	Independent variables and levels for Plackett-Burman screening design	96
Table 5-5	Plackett-Burman design experimental matrix and results	96
Table 5-6	Various critical material attributes along with their levels for optimization by Box-Behnken design	101
Table 5-7	Box-Behnken design experimental matrix and results	102
Table 5-8	ANOVA of full as well as reduced quadratic model for %EE	103
Table 5-9	ANOVA of full as well as reduced quadratic model for DI	104
Table 5-10	Model terms summary for full as well as reduced model of %EE and DI	105
Table 5-11	Coded coefficients of full as well as reduced model for %EE	105
Table 5-12	Coded coefficients of full as well as reduced model for DI	106
Table 5-13	Criteria for optimization of the PTX-UDNVs	109
Table 5-14	Summary of the optimization solution	109
Table 5-15	Results of verification trials	109
Table 6-1	Measures of qualitative risk assessment	115
Table 6-2	QTPP for CBP loaded UDNVs	118
Table 6-3	Qualitative Risk Assessment	120

Table 6-4	Independent variables and levels for Plackett-Burman screening design	122
Table 6-5	Plackett-Burman design experimental matrix and results	122
Table 6-6	Various critical material attributes along with their levels for optimization by Box-Behnken design	127
Table 6-7	Box-Behnken design experimental matrix and results	128
Table 6-8	ANOVA of full as well as reduced quadratic model for %EE	129
Table 6-9	ANOVA of full as well as reduced quadratic model for DI	130
Table 6-10	Model terms summary for full as well as reduced model of %EE and DI	130
Table 6-11	Coded coefficients of full as well as reduced model for %EE	131
Table 6-12	Coded coefficients of full as well as reduced model for DI	132
Table 6-13	Criteria for optimization of the CBP-UDNVs	135
Table 6-14	Summary of the optimization solution	136
Table 6-15	Results of verification trials	136
Table 7-1	In Vitro drug release of PTX-UDNVs and Plain Drug Suspension	147
Table 7-2	In Vitro drug release of PTX-UDNVs loaded IVR	148
Table 7-3	Drug permeation profile of PTX-UDNVs and Plain drug suspension	150
Table 7-4	Vesicle size and Entrapment of PTX-UDNVs initially and after re-dispersion of IVR	151
Table 7-5	In Vitro drug release of CBP-UDNVs and Plain Drug Solution	158
Table 7-6	In Vitro drug release of CBP-UDNVs loaded IVR	159
Table 7-7	Drug permeation profile of CBP-UDNVs and Plain drug solution	162
Table 7-8	Vesicle size and Entrapment of CBP-UDNVs initially and after re-dispersion of IVR	163
Table 8-1	Study sample codes and description for histopathology study	169
Table 9-1	IC50 values of PTX-marketed formulation and PTX-UDNVs	187
Table 9-2	IC50 values of CBP-marketed formulation and CBP-UDNVs	189
Table 10-1	Mean radiochemical purity for radiolabelled PTX	203
Table 10-2	Radiochemical purity of 99mTc-CBP	203
Table 10-3	In vitro stability of radiolabelled PTX (99mTc-PTX)	204
Table 10-4	DTPA transchelation study for 99mTc-PTX complex	205
Table 10-5	Results of biodistribution of 99mTc-PTX loaded UDNVs	207
Table 10-6	Results of biodistribution of 99mTc-PTX plain drug solution	207
Table 10-7	Quantitative systemic absorption study of 99mTc-PTX loaded UDNVs and plain drug	210
Table 11-1	Three month stability results of PTX and CBP UDNVs	221
Table 11-2	Three month stability results of PTX and CBP IVRs	222